Poster details advances in screening for non-hallucinogenic, neuroplastogen drug candidates for the treatment of mental health disorders CAMBRIDGE, Mass. - Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology…
Read More
Enveric utilizing AI-backed 3D modeling to identify potential non-hallucinogenic, neuroplastic tryptamine derivative NCEs for its EVM301 Series CAMBRIDGE, Mass. - Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology…
Read More
New patent provides additional composition of matter and methods of use claims for Enveric's tryptamine-derived prodrugs including EB-373, a new chemical entity psilocin prodrug CAMBRIDGE, Mass. - Enveric Biosciences (NASDAQ:…
Read More
CAMBRIDGE, Mass. - Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of anxiety, depression, and…
Read More
Composition of matter and methods of use claims encompass EB-373, Enveric's new chemical entity psilocin prodrug being developed for the treatment of anxiety disorder CAMBRIDGE, Mass. - Enveric Biosciences (NASDAQ:…
Read More
Composition of matter and methods of use claims encompass EB-373, Enveric's new chemical entity psilocin prodrug being developed for the treatment of anxiety disorder CAMBRIDGE, Mass. - Enveric Biosciences (NASDAQ:…
Read More
High purity of manufactured prodrug product allows Enveric and partners to ship EB-373 without being subject to restrictions required for controlled substances CAMBRIDGE, Mass. - Enveric Biosciences (NASDAQ: ENVB) ("Enveric"…
Read More
Advanced preclinical pipeline of neuroplastogenic small-molecule therapeutics targeting neuronal atrophy to offer a first-in-class treatment of mental health disorders Secured multiple Notices of Allowance and select issuances from the United…
Read More
Absorption, distribution, metabolism, and excretion (ADME) and toxicology assays demonstrated rapid conversion of EB-373 to the active metabolite psilocin, consistent with previously reported animal pharmacokinetic (PK) studies CAMBRIDGE, Mass. -…
Read More
Orally administered EB-373 resulted in dose-dependent increase in psilocin blood concentration in pharmacokinetic (PK) animal studies, correlating to levels expected to be effective based on psilocybin data in humans Outcome…
Read More
